← Browse by Condition

Medical Condition

breast neoplasms

Total Trials

18

Recruiting Now

18

Trial Phases

Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for breast neoplasms sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — breast neoplasms Clinical Trials

How many clinical trials are currently recruiting for breast neoplasms?

ClinicalMetric currently tracks 18 actively recruiting clinical trials for breast neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 18. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for breast neoplasms?

breast neoplasms research spans Phase 2 (5 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a breast neoplasms clinical trial?

Eligibility criteria for breast neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 2

5

Phase 3

3

Top Sponsors

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 1 trial

Cancer Research Antwerp 1 trial

Baylor Research Institute 1 trial

UNC Lineberger Comprehensive Cancer Center 1 trial

Second Affiliated Hospital, Zhejiang University, School of Medicine 1 trial

Recruiting Clinical Trials

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study

Fondazione IRCCS Istituto Nazi...

Preoperative Radiation Therapy and Immediate Breast Reconstruction

Cancer Research Antwerp

NCT06517212 Phase 2

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Baylor Research Institute

Dissemination of BREASTChoice AIM1-B

UNC Lineberger Comprehensive C...

NCT06464913 Phase 2

Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction

Second Affiliated Hospital, Zh...

ICG Lymphoscintigraphy Changes Before and After Radiotherapy in Breast Cancer Patients

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Sunnybrook Health Sciences Cen...

Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer

Lund University

Longitudinal Body Composition Assessment in Breast Cancer Patients

Taipei Tzu Chi Hospital, Buddh...

Impact of Prehabilitation and Comprehensive Follow-up in Women With Breast Cancer

European University Miguel de ...

NCT04722692 Phase 3

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

United States, Hong ...

Uppsala University

NCT04993014 Phase 2

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

AC Camargo Cancer Center

Evaluation of Clinical Efficacy of Augmented Reality (AR)-Based Breast Cancer Medical Imaging Solution (SKIA-Breast) Localization Method in Breast Cancer Patients

NCT06966700 Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

United States, Argen...

Merck Sharp & Dohme LLC

NCT06313463 Phase 3

Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy

Sun Yat-Sen Memorial Hospital ...

NCT04641247 Phase 2

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

United States, Austr...

GlaxoSmithKline

DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes

Hubei Cancer Hospital

NCT06974604 Phase 2

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

Brown University

Related Conditions

breast cancer (6) breast carcinoma (2) her2 positive breast cancer (2) radiomic (1) radiomics (1) breast cancer metastatic (1) breast cancer stage iv (1) breast cancer with bone metastasis (1) breast cancer with metastatic bone disease (1) trastuzumab (1) her2 (1) her2 breast cancer (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology